non-small cell lung cancer
Conditions
Interventions
experimental group:low-dose Decitabine plus Crizotinib
Sponsors
Department of Oncology, The Second Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 72 Years
Inclusion criteria
Inclusion criteria: Histologically or cytologically confirmed advanced (stage IV) non-squamous non-small-cell lung cancer. Testing for EGFR-mutation positive (exon 19 deletion, L858R) was performed in a central laboratory by using an amplification refractory mutation system or peripheral blood circulating tumor DNA testing, Crizotinib as fristline treatment in advanced non-small cell lung cancer patients without clinically unstable central nervous system (CNS) metastasis; Aged 18-72 years; Eastern Cooperative Oncology Group (ECOG) performance status of 0-3; Expected survival period for 3 months or more; Demonstrate adequate bone marrow, liver, renal, cardiac functions; Patients without severe disease conflicting with the therapy of lung cancer; Must have signed and dated an approved Informed Consent Form.
Exclusion criteria
Exclusion criteria: Resistance to methylation drugs; Prior therapy with methylation agents or other anti-tumor treatment, except for hormone replacement therapy; EGFR-mutation negative patients; Active uncontrolled infection; Any evidence of intestinal obstruction; Patients must not be receiving any other investigational agents for 4 weeks or less. Prior treatment with Steroidal antiemetic; Psychiatric illness or social situation that would limit compliance with study requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| median progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| median overall survival;Efficacy;Safety; | — |
Countries
China
Contacts
Public ContactJin-an Ma
Department of Oncology, The Second Xiangya Hospital of Central South University
Outcome results
None listed